Interleukin 22, a Potential Therapeutic Target for Rheumatoid Arthritis

To the Editor:
A recent report by Da Rocha, et al indicated that levels of interleukin 22 (IL-22) were increased in patients with rheumatoid arthritis (RA) compared with controls; levels of IL-22 correlated with Disease Activity Score (DAS28) and Clinical Disease Activity Index measures, rheumatoid factor positivity was correlated with higher levels of IL-22 in patients with RA, and the presence of bone erosions was associated with high IL-22 levels 1 . These findings suggest that IL-22 may be a good biomarker for assessment of activity in RA, and IL-22 seems to be a potential therapeutic target for RA.
Other studies have indicated the similar relationship between IL-22 and RA, where serum IL-22 levels were found to be increased in patients with RA compared with controls 2,3,4,5 , and high IL-22 levels correlated with bone erosions 4 . The IL-22 concentration in synovial fluid was higher in patients with RA compared with controls 2, 3 . In patients with RA, Th17 cells were recognized to produce higher IL-22 4 . Th22 cells also produced IL-22 and the expression of Th22 cells. IL-22 were significantly elevated in RA patients 5, 6 . More importantly, Th17/22 cells showed positive correlations with IL-22, C-reactive protein, and DAS28 data 6 . In addition, natural killer (NK)-22 cells in vitro can secrete higher levels of IL-22 and tumor necrosis factor-α (TNF-α), and NK-22 supernatant can induce the proliferation of RA fibroblast-like synoviocytes (FLS); however, addition of IL-22 antibody plus TNF-α antibody inhibited the proliferation of FLS induced by the NK-22 supernatant 7 . In vitro, human recombinant IL-22 (rhIL-22) significantly increased proliferation of RA synovial fluid and FLS and production of monocyte chemoattractant protein-1 3, 7, 8 , but an inhibitory effect of anti-IL-22R antibody on proliferation of FLS induced by rhIL-22 was found in RA 3 . Moreover, an experimental arthritis model (IL-1Ra−/−) displayed a progressive erosive arthritis characterized by upregulation of IL-22 in severely inflamed synovia; and anti-IL-22 treatment of IL-1Ra−/− mice significantly reduced the inflammation and bone erosions 9 . Similarly, in studies of collagen-induced arthritis (CIA), serum IL-22 levels were increased, and the specific IL-22RI was expressed in lymphoid tissue, including splenocytes. IL-22−/− mice were less susceptible to CIA than wild-type mice, as shown by their reduced incidence of arthritis and decreased pannus formation. Remarkably, the less severe form of arthritis in IL-22−/− mice was associated with increased production of collagen II-specific and total IgG antibodies. In vitro, IL-22 was found to promote osteoclastogenesis, a process that may contribute to its proinflammatory activity in CIA 10 . On the other hand, 1,25-dihydroxyvitamin D3 (1, 25 [OH]2D3) prevented corticosteroid-induced osteoporosis in patients with early RA, where 1,25[OH]2D3 directly modulated human Th17 polarization, accompanied by suppression of IL-17, TNF-α, and IL-22 production 11 . In patients with RA, rituximab reduced expression of IL-22 and Th17-positive cells in synovial tissue, and this correlated with better clinical outcomes. In vitro, rituximab strongly reduced IL-17 and IL-22 production induced by Candida albicans 12 .
These findings suggest therapeutic potential for patients with RA, and suggest a role for IL-22 in development of RA. Further studies are needed to clarify the role of IL-22 in RA. Therapeutic agents targeting IL-22 might result in innovative new therapies for RA. 
